A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non-Small Cell Lung Cancer Patients

Clinical Cancer Research

Volumn 22, Issue 15, 2016, Pages 3782-3790

  Rodriguez, Pedro C ^a   Popa, Xitllaly ^a   Martínez, Odeth ^b   Mendoza, Silvia ^c   Santiesteban, Eduardo ^d   Crespo, Tatiana ^e   Amador, Rosa M ^f   Fleytas, Ricardo ^g   Acosta, Soraida C ^h   Otero, Yanine ⁱ   Romero, Gala N ^j   De La Torre, Ana ^k   Cala, Mireysi ^l   Arzuaga, Lina ^m   Vello, Loisel ⁿ   Reyes, Delmairis ^o   Futiel, Niurka ^p   Sabates, Teresa ^q   Catala, Mauricio ^r   Flores, Yoanna I ^s   Garcia, Beatriz ^a   Viada, Carmen ^a   Lorenzo Luaces, Patricia ^a   Marrero, Maria A ^t   Alonso, Liuba ^t   Parra, Jenelin ^t   Aguilera, Nadia ^t   Pomares, Yaisel ^a   Sierra, Patricia ^a   Rodríguez, Gryssell ^a   Mazorra, Zaima ^a   Lage, Agustin ^a   Crombet, Tania ^a   Neninger, Elia ^u   more..

^a CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

^b Vladimir I Lenin University Hospital   (Cuba)

^c Manuel Ascunce University Hospital   (Cuba)

^d José L Lopez Tabranes University Hospital   (Cuba)

^e Benefico Jurídico Pneumological Hospital   (Cuba)

^f III Congreso University Hospital   (Cuba)

^g Pathology Department   (Cuba)

^h Saturnino Lora University Hospital   (Cuba)

ⁱ Camilo Cienfuegos University Hospital   (Cuba)

^j Carlos M de Céspedes University Hospital   (Cuba)

^k Celestino Hernández University Hospital   (Cuba)

^l Dr Juan B Zayas University Hospital   (Cuba)

^m Maria Curie University Hospital   (Cuba)

ⁿ Antonio Luaces University Hospital   (Cuba)

^o Ernesto Guevara University Hospital   (Cuba)

^p Celia Sánchez University Hospital   (Cuba)

^q Dr Gustavo Aldegueria University Hospital   (Cuba)

^r Medical Surgical Research Center   (Cuba)

^s National Oncology and Radiobiology Institute   (Cuba)

^t National Center for Coordination of Clinical Trials   (Cuba)

^u Hospital Clinicoquirúgico Hermanos Ameijeiras   (Cuba)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; MONTANIDE ISA 51; RECOMBINANT EPIDERMAL GROWTH FACTOR; CANCER VACCINE; IMMUNOLOGICAL ADJUVANT;

ADULT; ADVANCED CANCER; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; ASTHENIA; BLURRED VISION; BONE PAIN; BRONCHOSPASM; CANCER STAGING; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRY SKIN; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; HEADACHE; HUMAN; HYPERTENSION; HYPOTENSION; IMMUNOGENICITY; INJECTION SITE PAIN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; TREATMENT DURATION; URTICARIA; VOMITING; XEROSTOMIA; ACTIVE IMMUNOTHERAPY; BLOOD; CLINICAL TRIAL; KAPLAN MEIER METHOD; LUNG TUMOR; MORTALITY; PATHOLOGY; PROGNOSIS; RETREATMENT; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; IMMUNOTHERAPY, ACTIVE; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; PROGNOSIS; RETREATMENT; TREATMENT OUTCOME;

EID: 84980322935     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-0855     Document Type: Article

References (30)

1. World Health Organization. Lyon, France: International Agency for Research on Cancer; Feb 3, 2014. Press Release No. 224. Available from: http://www.iarc.fr/en/media-centre/pr/2014/pdfs/pr224-E.pdf
2. DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 2014;64:252-71.
3. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinumbased chemotherapy. J Clin Oncol 2000;18:2095-103.
4. Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, doubleblind, phase 3 study. Lancet 2009;374:1432-40.
5. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32.
6. Karachaliou N, Rosell R. Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond. Cancer Biol Med 2014;11:173-81.
7. Toyooka S, Mitsudomi T, Soh J, Aokage K, Yamane M, Oto T, et al. Molecular oncology of lung cancer. Gen Thorac Cardiovasc Surg 2011;59:527-37.
8. Avraham R, Yarden Y. Feedback regulation of EGFR signalling: decision making by early and delayed loops. Nat Cancer Mol Cell Biol 2011; 12:104-17.
9. Hirsch FR, Varella-Garcia M, Bunn PA Jr, Di Maria MV, Veve R, Bremmes RM, et al. Epidermal growth factor receptor in non-smallcell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003;21: 3798-807.
10. Gonzalez G, Lage A. Cancer vaccines for hormone/growth factor immune deprivation: a feasible approach for cancer treatment. Curr Cancer Drug Targets 2007;7:229-41.
11. Gonzalez G, Crombet T, Catala M, Mirabal V, Hernández JC, González Y, et al. A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: report of a pilot clinical trial. Ann Oncol 1998;9:431-5.
12. Gonzalez G, Crombet T, Torres F, Catala M, Alfonso L, Osorio M, et al. Epidermal growth factor based cancer vaccine for non-small-cell lung cancer therapy. Ann Oncol 2003;14:461-6.
13. Crombet T, Neninger E, Catala M, García B, Leonard I, Martínez L, et al. Treatment of NSCLC patients with an EGF-based cancer vaccine: report of a phase I trial. Cancer Biol Ther 2006;5:130-40.
14. Neninger Vinageras E, de la Torre A, Osorio Rodríguez M, Catalá Ferrer M, Bravo I, Mendoza del Pino M, et al. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced NSCLC. J Clin Oncol 2008;26:1452-8.
15. García B, Neninger E, de la Torre A, Leonard I, Martínez R, Viada C, et al. Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine. Clin Cancer Res 2008;141:840-6.
16. Rodriguez G, Albisa A, Viña L, Cuevas A, Garcia B, Garcia AT, et al. Manufacturing process development for an epidermal growth factor-based cancer vaccine. BioPharm Int Suppl 2008;10:31-42.
17. Fine GD. Consequences of delayed treatment effect on analysis to time to event end points. Drug Inf J 2007;41:535-9.
18. LambertPC, Royston P. Furtherdevelopment offlexible parametric models for survival analysis. Stata J 2009;9:265-90.
19. Khozin S, Blumenthal GM, Zhang L, Tang S, Brower M, Fox E, et al. FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer. Clin Cancer Res 2015; 21:2436-9.
20. Camidge DR, Pao W, Sequist LV. Acquired resistance to TKIs in solid tumours: learning from lung cancer. Nat Rev Clin Oncol 2014; 11:473-81.
21. Kazandjian D, Khozin S, Blumenthal G, Zhang L, Tang S, Libeg M, et al. Benefit-risk summary of nivolumab for patients with metastatic squamous cell lung cancer after platinum-based chemotherapy: a report from the US Food and Drug Administration. JAMA Oncol 2015;15:1-5.
22. Socinski MA. Incorporating immunotherapy into the treatment of nonsmall cell lung cancer: practical guidance for the clinic. Semin Oncol 2015;42(Suppl 2):S19-28.
23. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2011;372:2018-28.
24. Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol 2014;15:59-68.
25. Quoix E, Ramlau R, Westeel V, Papai Z, Madroszyk A, Riviere A, et al. Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial. Lancet Oncol 2011;12:1125-33.
26. Nemunaitis J, Nemunaitis M, Senzer N, Snitz P, Bedell C, Kumar P, et al. Phase II trial of Belagenpumatucel-L, a TGF-beta2 antisense gene modified allogeneic tumor vaccine in advanced non- small cell lung cancer (NSCLC) patients. Cancer Gene Ther 2009;16:620-4.
27. Giraldo NA, Becht E, Remark R, Damotte D, Sautès-Fridman C, Fridman WH, et al. The immune contexture of primary and metastatic human tumours. Curr Opin Immunol 2014;27:8-15.
28. Hoos A, Parmiani G, Hege K, Sznol M, Loibner H, Eggermont A, et al. A clinical development paradigm for cancer vaccines and related biologics. J Immunother 2007;30:1-15.
29. Dillman RO. Cancer vaccines: can they improve survival? Cancer Biother Radiopharm 2015;30:147-51.
30. Freidlin B, Korn EL. Biomarker enrichment strategies: matching trial design to biomarker credentials. Nat Rev Clin Oncol 2014;11:81-90.